{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:18:41Z","timestamp":1771013921762,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T00:00:00Z","timestamp":1082592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> There are no data comparing the relative efficacy of hydrofluoroalkane (HFA) formulations of ciclesonide (CIC) and fluticasone propionate (FP) on airway hyper\u2010responsiveness, in mild\u2010to\u2010moderate persistent asthma. We therefore elected to evaluate the comparative efficacy of HFA pressurized metered\u2010dose inhaler formulations of CIC and FP, assessing methacholine challenge, in addition to exhaled nitric oxide, lung function, diary cards and quality of life.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Nineteen mild\u2010to\u2010moderate asthmatic patients completed the study per protocol in randomized, double\u2010blind, double\u2010dummy, crossover fashion. Patients were required to stop their usual inhaled corticosteroid therapy for the duration of the study. Pa\u2010tients were commenced instead on salmeterol (SM) 50\u2003\u00b5g one puff twice daily\u2003+ montelukast (ML) 10\u2003mg once daily for 2\u2010week washout periods prior to each randomized treatment, in order to prevent dropouts. Patients received 4\u2003weeks of either CIC 200\u2003\u00b5g two puffs once daily (08.00\u2003h)\u2003+\u2003CIC\u2010placebo (PL) two puffs once daily (20.00\u2003h)\u2003+\u2003FP\u2010PL two puffs twice daily (08.00\u2003h and 20.00\u2003h), or FP 125\u2003\u00b5g two puffs twice daily (08.00\u2003h and 20.00\u2003h)\u2003+\u2003CIC\u2010PL two puffs twice daily (08.00\u2003h and 20.00\u2003h). SM\u2003+\u2003ML were withheld for 72\u2003h prior to post\u2010washout visits and CIC or FP was withheld for 24\u2003h prior to study visits.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> There was no significant difference between CIC <jats:italic>vs.<\/jats:italic> FP for the primary outcome of methacholine P<jats:italic>C<\/jats:italic><jats:sub>20<\/jats:sub> as doubling dilution (dd) shift from respective baseline; mean difference: 0.4 dd (95% CI \u22120.4, 1.2). Moreover, there was no difference between treatments for the sequence of CIC first <jats:italic>vs<\/jats:italic> FP second; mean difference: 0.2 dd (95% CI \u22121.3, 1.7) or FP first <jats:italic>vs<\/jats:italic> CIC second; mean difference: 0.9 dd (95% CI \u22120.1, 1.8). There were also no differences for other secondary outcomes between treatments, either respective or irrespective of sequence, as change from baseline.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> There were no differences between 4\u2003weeks of CIC 400\u2003\u00b5g once daily and FP 250\u2003\u00b5g twice daily on methacholine hyper\u2010responsiveness in mild\u2010to\u2010moderate persistent asthma. Longer\u2010term studies are indicated to evaluate their relative efficacy on asthma exacerbations.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2004.02108.x","type":"journal-article","created":{"date-parts":[[2004,6,21]],"date-time":"2004-06-21T08:09:15Z","timestamp":1087805355000},"page":"26-33","source":"Crossref","is-referenced-by-count":34,"title":["Effects of hydrofluoroalkane formulations of ciclesonide 400\u2003\u00b5g once daily <i>vs<\/i> fluticasone 250\u2003\u00b5g twice daily on methacholine hyper\u2010responsiveness in mild\u2010to\u2010moderate persistent asthma"],"prefix":"10.1111","volume":"58","author":[{"given":"Daniel K. C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Haggart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme P.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline E.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,6,4]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"S141","article-title":"Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics \u2013 2002","volume":"110","author":"National Asthma Education and Prevention Program.","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thorax.58.1.1","volume":"58","author":"British guidelines on the management of asthma.","year":"2003","journal-title":"Thorax"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7307.253"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.5.496"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00435-0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11679-5"},{"key":"e_1_2_6_8_2","first-page":"78","article-title":"Ciclesonide (Byk Gulden)","volume":"3","author":"Dent G","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002250998"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70043-6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1612"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(00)80143-2"},{"key":"e_1_2_6_13_2","first-page":"S29","article-title":"Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French Study Group","volume":"94","author":"Tonnel AB","year":"2000","journal-title":"Respir Med"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.2.618"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.ats11-99"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.3.7663792"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10071683"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14a08.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01813.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.120559"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.6.500"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9809046"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2004.02108.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2004.02108.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:44:28Z","timestamp":1697237068000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2004.02108.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1365-2125.2004.02108.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02108.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,4]]}}}